Metformin HCl Reduces Vocal Fold Fibrosis via AMPK Modulation

Study Background and Research Question

Vocal fold fibrosis is a persistent and debilitating disorder resulting from injury, inflammation, or surgical intervention, often culminating in scar tissue formation and impaired voice quality. Despite the availability of treatments such as voice therapy, surgical repair, and corticosteroid injections, outcomes remain suboptimal due to incomplete tissue restoration, risk of further scarring, and recurrence. The complex pathophysiology involves excessive collagen deposition and myofibroblast differentiation, regulated chiefly by the TGF-β/Smad signaling axis and chronic inflammatory mediators. Given the established antifibrotic effects of Metformin Hydrochloride (Metformin HCl) in other organ systems, the central research question addressed by Cai et al. (Inflammation, 2025) is whether metformin can attenuate vocal fold fibrosis via modulation of the AMP-activated protein kinase (AMPK) signaling pathway in a validated animal model.

Key Innovation from the Reference Study

The principal innovation of this study lies in establishing a mechanistic link between metformin's activation of AMPK and the attenuation of fibrosis within the unique context of vocal fold tissue. While previous research has explored the antifibrotic properties of metformin in lung and renal models, this work is the first to apply a rigorous, multi-modal approach (including in vivo and in vitro systems) for vocal fold scarring. The study not only demonstrates a reduction in canonical fibrotic markers (COL1A1, α-SMA, TGF-β, Smad2/3) but also provides evidence that these effects are dependent on AMPK activation, as confirmed by pharmacological inhibition with Compound C. This positions metformin as a promising AMPK signaling pathway modulator for fibrotic laryngeal disorders.

Methods and Experimental Design Insights

The research utilized a two-pronged approach:

• In vivo rabbit model: Vocal fold injury was induced in New Zealand White rabbits. Two weeks post-injury, animals received intraperitoneal injections of metformin at 250 mg/kg. Four weeks after injury, vocal folds were harvested for histological and molecular analyses.
• In vitro fibroblast model: Primary rabbit vocal fold fibroblasts were cultured and treated with metformin (10 μM), with or without TGF-β1 stimulation (10 ng/mL). To test the specificity of the AMPK pathway, some cultures received Compound C (10 μM), an AMPK inhibitor.

Comprehensive assessment included:

• Masson's trichrome staining to evaluate collagen deposition and lamina propria architecture.
• Immunohistochemical labeling and quantitative real-time PCR (qPCR) for expression of key fibrotic markers (COL1A1, α-SMA, TGF-β, Smad2, Smad3).
• Western blotting to probe pathway activation and downstream effector status.

This multi-level design enabled the team to dissect both tissue-level and cellular signaling changes in response to metformin intervention.

Protocol Parameters

• Metformin dosing (in vivo): 250 mg/kg via intraperitoneal injection, administered two weeks post-injury for established fibrosis modeling (reference study).
• Fibroblast culture (in vitro): Metformin at 10 μM, with or without TGF-β1 (10 ng/mL), for 24–48 hours.
• AMPK inhibition control: Compound C at 10 μM as a pathway-specific inhibitor.
• Histological analysis: Masson's trichrome for collagen; immunohistochemistry/qPCR for marker quantification.
• Workflow recommendations: For solubility and reproducibility, metformin is typically prepared in DMSO with gentle warming or sonication, at concentrations ranging from micromolar (cellular) to millimolar (animal studies), as described in the product information.

Core Findings and Why They Matter

According to the study, metformin treatment significantly improved the structural integrity of the vocal fold lamina propria, reduced pathologic collagen deposition, and lowered the expression of profibrotic markers COL1A1 and α-SMA. At the molecular level, metformin activated the AMPK pathway, resulting in suppressed TGF-β/Smad signaling—a key axis in myofibroblast activation and extracellular matrix synthesis. The specificity of this effect was confirmed by the reversal of antifibrotic outcomes upon co-treatment with Compound C. Importantly, these changes were observed both in animal tissue and cultured fibroblasts, suggesting a robust and cell-autonomous effect. These findings matter because they expand the therapeutic landscape for vocal fold fibrosis—an area with substantial unmet clinical need—by providing a molecular rationale for repurposing metformin as a lipid biosynthesis attenuation and fatty acid oxidation promoter in fibrotic laryngeal disease. The mechanistic focus on AMPK also opens avenues for precision targeting of metabolic and signaling pathways in vocal tissue repair.

Comparison with Existing Internal Articles

Recent internal resources have highlighted Metformin Hydrochloride's versatility in modulating fibrotic and metabolic processes beyond glycemic control. For example, Metformin Hydrochloride in Fibrosis Research: Protocols & Pitfalls discusses protocol adjustments and troubleshooting for metformin-based modulation of the AMPK pathway in complex fibrosis models, including vocal fold injury. This aligns closely with the reference study’s approach to dosing, cell model validation, and pathway interrogation. Additionally, research such as Metformin Suppresses Achilles Tendon Ossification via Nr4a1/Wnt/β-catenin Inhibition and Metformin HCl Suppresses Tendon HO via Nr4a1/Wnt/β-catenin Inhibition extends metformin’s antifibrotic and anti-ossification effects to musculoskeletal models, highlighting its role in limiting aberrant differentiation and extracellular matrix remodeling. Though the signaling axes differ (AMPK for vocal fold, Nr4a1/Wnt for tendon), these studies collectively underscore metformin’s unique position as a multi-pathway modulator in tissue repair and fibrosis contexts. For broader mechanistic context, Metformin Hydrochloride: Mechanistic Insights & Translational Impact bridges translational metabolism with tissue-specific repair, emphasizing metformin’s capacity for AMPK activation, inhibition of hepatic gluconeogenesis, and suppression of pathological matrix production across diverse models.

Limitations and Transferability

While the study’s findings are compelling, several limitations warrant consideration. First, the use of a rabbit model, while anatomically and physiologically relevant, may not fully recapitulate human vocal fold biology or the chronicity of human fibrotic disease. Second, the relatively short duration (four weeks post-injury) may not capture long-term remodeling or potential recurrence. Dose translation from animal to human systems also requires careful pharmacokinetic and safety evaluation. Furthermore, while AMPK activation was necessary for antifibrotic effects in this model, off-target or compensatory pathways may influence outcomes in other tissue environments. Thus, while the results strongly support the utility of metformin as an AMPK signaling pathway modulator in vocal fold fibrosis, further studies—including human cell/tissue models and longer-term trials—are needed to establish clinical translatability and optimize dosing strategies.

Research Support Resources

For researchers aiming to replicate or extend these findings, Metformin Hydrochloride (Metformin HCl) (SKU B1970) is available as a research-grade compound for in vitro and in vivo applications. Detailed protocol guidance, including recommended solubility and storage parameters, can be found in the product specification. This resource supports standardized workflows for AMPK signaling pathway studies and fibrosis modeling. APExBIO provides validated material suitable for diverse experimental designs, from primary cell assays to animal models exploring the inhibition of hepatic gluconeogenesis and targeted metabolic modulation.